Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P250025/S002

TorEx Lung Perfusion System; TorEx Lung Perfusate

Traferox Technologies, Inc. · Decision date Oct 30, 2026

FDA DECISIONP250025/S002

What did the FDA approve?

FDA records P250025/S002 as a supplement to PMA P250025, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Oct 30, 2026.

FDA approval order statement

Approval of the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P250025.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Gastroenterology, Urology
Decision date
Oct 30, 2026
FDA change category
Postapproval Study Protocol

FDA source record

Regulatory record facts

Identifier
P250025/S002
Regulatory pathway
PMA supplement
Product code
PHO
Decision code
APPR
Decision date
Oct 30, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Normothermic preservation system for transplantation of initially unacceptable donor lungs.

Product code
PHO
FDA device class
3

For the original device and its historical approval scope, see PMA P250025. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P250025 · Original PMA

    TorEx Lung Perfusion System

  2. P250025/S002 received

    Application receipt date recorded by FDA.

  3. P250025/S001 · Related supplement

    TorEx Lung Perfusion System; TorEx Lung Perfusate

  4. P250025/S002 · FDA decision

    Normal 180 Day Track No User Fee

Timeline entries are records held by MedtechLedger for P250025. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250025

Product / regulatory recordCompanyPathwayDecision dateSource
Traferox Technologies, Inc.PMA approvalJul 15, 2026FDA
Traferox Technologies, Inc.PMA supplementOct 30, 2026FDA

Explore the linked device profile

Other records with product code PHO

Product / regulatory recordCompanyPathwayDecision dateSource
LungFX DeviceP240033/S001
Lung Bioengineering, Inc.PMA supplementOct 16, 2026FDA
LungFX DeviceP240033/S002
Lung Bioengineering, Inc.PMA supplementOct 16, 2026FDA
Xvivo Perfusion, Inc.PMA supplementSep 16, 2026FDA
Lung Bioengineering, Inc.PMA approvalJun 22, 2026FDA
Xvivo Perfusion, Inc.PMA approvalApr 26, 2019FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Traferox Technologies, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
3505 Laird Rd., Unit 16, Mississauga, L5L 5Y7

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records